Thus, inhibitors of PARP1 or CD38 were used to prevent the reduction in cellular NAD pools during pathologic conditions such as ischemia and traumatic brain injury, or in models of Alzheimer’s and Parkinson’s disease [95,96,97,98]. This evidence concerns the gene PARP1 and Parkinson disease.